Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that, through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for high functioning adults, the most reliable fast acting edibles on the market will now be available across the country. According to the … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Nuka to Expand Cannabis Product Operations for DehydraTECH Powered Edibles”
The company aims to promote healthier administration methods, eliminating the need for sweeteners to mask taste Lexaria’s mission is to save lives with its technology, which allows for delivery of drug molecules through ingestible means The company is seeing high demand in North American markets for DehydraTECH in cannabis-infused beverages Lexaria recently announced its entry … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Responds to High Demand for Cannabis-Infused Beverages”
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Outperforms Conventional Industry Formulations in Animal Testing”
LXRP recently added multiple highly respected experts to its scientific advisory board The company is readying for growth by ensuring executive continuity LXRP continues to conduct research regarding oral nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has bolstered its future growth prospects by adding four new members to its scientific advisory board and renewing … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Adds Four Members to Advisory Board, Renews Executive Contracts”
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its entry into a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp. Under the agreement, Lexaria will provide its patented DehydraTECH(TM) technology to a private Nevada-based company for utilization in certain CBD-based beverages that will be produced and … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters CBD-Beverage Formulation License Agreement via Subsidiary”
Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio The company out-licenses disruptive delivery technology, giving licensees access to existing patents Lexaria entered into a new beverage license agreement with a California-based cannabis firm The company recently announced four new appointments to its scientific advisory board Lexaria Bioscience Corp. … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters New Licensing Agreement, Strengthens Business Model”
LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts The new contract agreements are designed to provide management security with continuity of key officers The company recently canceled 1,140,000 stock options after negotiations with optionees Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has successfully negotiated new three-year compensation contracts with … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Execs Sign Three-Year Contract Extensions, Ensuring Management Continuity”
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids”
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement to provide Lexaria’s patented DehydraTECH(TM) technology to a private California-based cannabis company. Under the agreement the cannabis company will utilize the technology in certain cannabis-based … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Advisory Board; Subsidiary Enters Beverage License Agreement”
Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products”
